The PIPE financing of at least $150 million provides the combined company with substantial cash runway, de-risking the post-merger entity. Monitor the S-4 registration statement effectiveness and stockholder vote timelines as key catalysts. The CVR structure for Aethlon shareholders creates a contingent value component tied to future cash distributions.
Price Chart
Executive Summary
Aethlon Medical (AEMD) filed the definitive merger agreement to acquire North Immunology, Inc. in a reverse-merger transaction. Aethlon will issue shares to North Immunology stockholders based on a formula valuing North Immunology at $150 million and Aethlon at $16.5 million (subject to net cash adjustments). Concurrently, North Immunology is raising at least $150 million (minimum $175 million) in a PIPE financing from institutional investors, which will close substantially concurrently with the merger. The combined entity will operate as 'North Immunology, Inc.' and continue trading on Nasdaq. This is a transformative reverse merger that effectively hands control of the public shell to North Immunology's shareholders and provides the combined company with significant cash runway.
Key Financial Metrics
Key Facts
- Aethlon Medical (AEMD) to acquire North Immunology in a reverse merger structured as a tax-free reorganization.
- North Immunology valued at $150 million; Aethlon valued at $16.5 million (subject to net cash adjustments).
- Concurrent PIPE financing of at least $150 million (minimum $175 million) from institutional investors.
- Combined entity to be named 'North Immunology, Inc.' and continue trading on Nasdaq.
- Aethlon shareholders will receive contingent value rights (CVRs) for potential additional consideration.
- Transaction expected to close by June 17, 2027, subject to stockholder and regulatory approvals.
Financial Impact
North Immunology valued at $150 million; Aethlon valued at $16.5 million; PIPE financing of at least $150 million (minimum $175 million).
Risk Factors
- Stockholder approval required from both Aethlon and North Immunology shareholders; failure could terminate the deal.
- Regulatory approvals, including HSR Act clearance, are conditions precedent to closing.
- The PIPE financing is subject to conditions; failure to raise minimum $150 million could scuttle the merger.
- Aethlon's existing business is being wound down; post-merger entity depends entirely on North Immunology's pipeline.
- CVRs are contingent and may pay zero if certain cash thresholds are not met.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001683168-26-007208 |
| Document: aethlon_ex1004.htm | 0001683168-26-007208 |
| Document: aethlon_ex1005.htm | 0001683168-26-007208 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G | $5.05 $5.07 | ▲ +0.40% | ▼ −0.06% | $5.21 (+3.17%) |
Oct 1, 2026 25d ago | 8-K | $6.45 $6.05 | ▲ +6.20% | ▲ +7.36% | $5.21 (+19.22%) |
Sep 17, 2026 5w ago | 425 | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.21 (−23.16%) |
Sep 17, 2026 5w ago | 8-K | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.21 (−23.16%) |
Sep 15, 2026 6w ago | 8-K | $1.47 $6.31 | ▲ +329.25% | ▲ +328.43% | $5.21 (+254.42%) |
Sep 4, 2026 7w ago | DEFA14A | $1.81 $1.47 | ▲ +18.78% | ▲ +17.67% | $5.21 (−187.85%) |
Aug 31, 2026 8w ago | 8-K | $2.06 $1.81 | ▼ −12.14% | ▼ −11.99% | $5.21 (+152.91%) |
Aug 13, 2026 10w ago | Press Release | $2.83 $2.73 | ▼ −3.53% | ▼ −2.17% | $5.21 (+84.10%) |
Jul 31, 2026 12w ago | 8-K | $0.6628 $0.6300 | ▲ +4.95% | ▲ +8.46% | $5.21 (−686.06%) |
Jul 7, 2026 16w ago | EFFECT | $0.7297 $0.6850 | ▲ +6.13% | ▲ +6.68% | $5.21 (−613.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers